B Mirror Report : Trading of the Global Depositary Receipts (GDRs) of Beximco Pharmaceuticals PLC on the London Stock Exchange (LSE) has officially resumed from June 26, 2026, following the withdrawal of a trading suspension.

According to a press release issued by the DSE Brokers Association of Bangladesh (DBA) on Saturday, Beximco Pharmaceuticals, the only Bangladeshi company listed on the LSE since 2004, had its GDR trading suspended on January 2, 2026. The suspension resulted from the company’s failure to publish its audited financial statements for the fiscal year ended June 30, 2025, along with subsequent financial reports within the required deadlines.

Under LSE listing rules, a security suspended for more than six months may face delisting if the reasons for the suspension are not resolved. With the deadline approaching on July 2, 2026, foreign institutional and individual investors requested the Bangladesh Securities and Exchange Commission (BSEC) and the DBA to take urgent action.

The DBA, led by President Saiful Islam, coordinated with the BSEC and Beximco Pharmaceuticals to resolve the issue. The BSEC approved a special board meeting, where the company finalized and published its outstanding quarterly and annual financial statements.

After the reporting deficiencies were addressed, the London Stock Exchange lifted the suspension, allowing GDR trading to resume.

The DBA welcomed the decision, saying it would strengthen the international reputation of Bangladesh’s capital market, increase foreign investors’ confidence, and improve the country’s position in global financial markets. The association also expressed gratitude to the government, the BSEC, Beximco Pharmaceuticals, and the media for their cooperation and hoped that further investor-friendly reforms would continue to attract more foreign investment to Bangladesh.